> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guide on Generic Abuse-deterrent Opioids
- URL: https://www.fdaweb.com/guide-on-generic-abuse-deterrent-opioids/
- Published: 2017-11-22T12:00:00.000Z
- Updated: 2026-09-14T23:03:13.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140188

*Federal Register* notice: FDA has made available a guidance entitled “General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products.”’ The document recommends studies, including comparative *in vitro* and pharmacokinetic studies, that a potential ANDA applicant should conduct and submit to FDA to demonstrate that a generic solid oral opioid drug product is no less abuse deterrent than its reference listed drug. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-11-22/pdf/2017-25248.pdf?ref=fdaweb.com).